Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%

Eli Lilly and Company (NYSE:LLYGet Free Report) traded down 0.5% during trading on Friday . The company traded as low as $876.00 and last traded at $878.94. 560,857 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 2,935,530 shares. The stock had previously closed at $883.33.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Tuesday. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $787.53.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Price Performance

The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market cap of $833.89 billion, a price-to-earnings ratio of 129.88, a PEG ratio of 1.89 and a beta of 0.36. The stock has a 50-day moving average price of $784.08 and a two-hundred day moving average price of $715.56.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were given a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.59%. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 192,794 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the completion of the sale, the insider now owns 98,208,810 shares of the company’s stock, valued at approximately $81,490,724,273.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 192,794 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $829.77, for a total value of $159,974,677.38. Following the transaction, the insider now owns 98,208,810 shares of the company’s stock, valued at approximately $81,490,724,273.70. The disclosure for this sale can be found here. Insiders sold 552,804 shares of company stock valued at $462,119,714 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of LLY. Campbell & CO Investment Adviser LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $234,000. Oliver Lagore Vanvalin Investment Group increased its stake in shares of Eli Lilly and Company by 24.7% in the 3rd quarter. Oliver Lagore Vanvalin Investment Group now owns 303 shares of the company’s stock valued at $163,000 after purchasing an additional 60 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Eli Lilly and Company by 324.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,069 shares of the company’s stock valued at $574,000 after purchasing an additional 817 shares in the last quarter. Altiora Financial Group LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at about $244,000. Finally, Kestra Advisory Services LLC increased its stake in shares of Eli Lilly and Company by 2.7% in the 3rd quarter. Kestra Advisory Services LLC now owns 58,978 shares of the company’s stock valued at $31,679,000 after purchasing an additional 1,531 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.